SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank45
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P45
Within normal range
vs 3Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q4 2025-35.71%
Q3 2025-82.48%
Q2 20258.28%
Q1 202516.40%
Q4 2024-45.90%
Q3 202418.45%
Q2 202429.04%
Q1 202418.26%
Q4 2023-157.27%
Q3 2023-6.73%
Q2 2023-202.51%
Q1 2023-1743.98%
Q4 2022101.20%
Q3 2022-63.06%
Q2 202253.55%
Q1 2022-50.48%
Q4 2021-1371.72%
Q3 2021105.78%
Q2 2021-230.22%
Q1 20210.00%
Q4 20200.00%